The reporting of prostate cancer on needle biopsy

Prognostic and therapeutic implications and the utility of diagnostic markers

Research output: Contribution to journalArticle

Abstract

Prostate needle biopsy remains the gold standard for diagnosing prostate cancer. Prostate cancer on needle biopsy can be evaluated by numerous techniques of quantifying tumour extent, Gleason score, and the presence of perineural invasion (PNI). These modalities can help clinicians in assessing the risk of extraprostatic disease, progression likelihood, and in helping men with prostate cancer choose among therapeutic options. This review details the information that should be included in the routine pathology report. Recent advances in molecular biology of prostate carcinogenesis have identified many molecular markers for prostate cancer. While several are extremely promising as diagnostic immunohistochemical markers, other prognostic markers are not yet ready to be used in routine practice until they are validated by large prospective studies.

Original languageEnglish (US)
Pages (from-to)472-479
Number of pages8
JournalPathology
Volume35
Issue number6
DOIs
StatePublished - 2003

Fingerprint

Needle Biopsy
Prostatic Neoplasms
Prostate
Neoplasm Grading
Therapeutics
Disease Progression
Molecular Biology
Carcinogenesis
Prospective Studies
Pathology
Neoplasms

Keywords

  • Prostate biopsy
  • Prostate cancer
  • Staging
  • Tumour markers

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{c8c14e156f924f6196b7756317cd5c38,
title = "The reporting of prostate cancer on needle biopsy: Prognostic and therapeutic implications and the utility of diagnostic markers",
abstract = "Prostate needle biopsy remains the gold standard for diagnosing prostate cancer. Prostate cancer on needle biopsy can be evaluated by numerous techniques of quantifying tumour extent, Gleason score, and the presence of perineural invasion (PNI). These modalities can help clinicians in assessing the risk of extraprostatic disease, progression likelihood, and in helping men with prostate cancer choose among therapeutic options. This review details the information that should be included in the routine pathology report. Recent advances in molecular biology of prostate carcinogenesis have identified many molecular markers for prostate cancer. While several are extremely promising as diagnostic immunohistochemical markers, other prognostic markers are not yet ready to be used in routine practice until they are validated by large prospective studies.",
keywords = "Prostate biopsy, Prostate cancer, Staging, Tumour markers",
author = "Ming Zhou and Epstein, {Jonathan Ira}",
year = "2003",
doi = "10.1080/00313020310001619163",
language = "English (US)",
volume = "35",
pages = "472--479",
journal = "Pathology",
issn = "0031-3025",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The reporting of prostate cancer on needle biopsy

T2 - Prognostic and therapeutic implications and the utility of diagnostic markers

AU - Zhou, Ming

AU - Epstein, Jonathan Ira

PY - 2003

Y1 - 2003

N2 - Prostate needle biopsy remains the gold standard for diagnosing prostate cancer. Prostate cancer on needle biopsy can be evaluated by numerous techniques of quantifying tumour extent, Gleason score, and the presence of perineural invasion (PNI). These modalities can help clinicians in assessing the risk of extraprostatic disease, progression likelihood, and in helping men with prostate cancer choose among therapeutic options. This review details the information that should be included in the routine pathology report. Recent advances in molecular biology of prostate carcinogenesis have identified many molecular markers for prostate cancer. While several are extremely promising as diagnostic immunohistochemical markers, other prognostic markers are not yet ready to be used in routine practice until they are validated by large prospective studies.

AB - Prostate needle biopsy remains the gold standard for diagnosing prostate cancer. Prostate cancer on needle biopsy can be evaluated by numerous techniques of quantifying tumour extent, Gleason score, and the presence of perineural invasion (PNI). These modalities can help clinicians in assessing the risk of extraprostatic disease, progression likelihood, and in helping men with prostate cancer choose among therapeutic options. This review details the information that should be included in the routine pathology report. Recent advances in molecular biology of prostate carcinogenesis have identified many molecular markers for prostate cancer. While several are extremely promising as diagnostic immunohistochemical markers, other prognostic markers are not yet ready to be used in routine practice until they are validated by large prospective studies.

KW - Prostate biopsy

KW - Prostate cancer

KW - Staging

KW - Tumour markers

UR - http://www.scopus.com/inward/record.url?scp=0346786294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346786294&partnerID=8YFLogxK

U2 - 10.1080/00313020310001619163

DO - 10.1080/00313020310001619163

M3 - Article

VL - 35

SP - 472

EP - 479

JO - Pathology

JF - Pathology

SN - 0031-3025

IS - 6

ER -